Web Analytics

fundsforNGOs

Grants and Resources for Sustainability

You are here: Home / Fellowship / Pfizer Research Grant Program for Studies in Relapsed or Refractory Diffuse Large B-Cell Lymphoma (US)

Pfizer Research Grant Program for Studies in Relapsed or Refractory Diffuse Large B-Cell Lymphoma (US)

Deadline: 16-Mar-2026

Pfizer is inviting applications for an independent research funding opportunity supporting interventional investigator-sponsored studies on brentuximab vedotin in relapsed or refractory diffuse large B-cell lymphoma (DLBCL) in the United States. The program aims to generate clinical evidence to optimize the use of brentuximab vedotin, particularly in pre-CAR-T and peri-CAR-T treatment settings, with funding of up to USD 500,000 per project.

Overview

Pfizer is seeking applications for a competitive grant program supporting interventional investigator-sponsored studies focused on brentuximab vedotin in patients with relapsed or refractory diffuse large B-cell lymphoma.

The program is designed to advance clinical understanding of how brentuximab vedotin can be optimally used as monotherapy or in combination with other approved agents across complex treatment pathways, including CAR-T related settings.

All supported studies must be conducted within the United States and remain fully independent in scientific design and execution.

Scientific and Clinical Focus Areas

This funding opportunity prioritizes research that addresses key evidence gaps in the real-world and clinical use of brentuximab vedotin in relapsed or refractory DLBCL.

Priority Research Themes

Supported studies should focus on one or more of the following areas:

  • Use of brentuximab vedotin as monotherapy in relapsed or refractory DLBCL

  • Combination regimens involving brentuximab vedotin and other approved agents

  • Pre-CAR-T treatment strategies incorporating brentuximab vedotin

  • Peri-CAR-T treatment approaches to optimize sequencing and patient outcomes

  • Clinical decision-making in complex treatment pathways for large B-cell lymphoma

The goal is to generate high-quality interventional evidence that informs clinical practice and treatment optimization.

What Is an Investigator-Sponsored Study?

An investigator-sponsored study (ISS) is an independent research project where:

  • The investigator designs and conducts the study

  • The investigator’s institution holds regulatory responsibility

  • Pfizer provides funding but does not control study execution

  • Scientific independence is maintained throughout the research lifecycle

This ensures unbiased data generation while aligning with Pfizer’s oncology and hematology research interests.

Funding Amount and Project Duration

Available Funding

  • Maximum funding per project: up to USD 500,000

  • Funding may include direct costs, indirect costs, and institutional overhead, in line with Pfizer policy

Project Timeline

  • Maximum project duration: up to four years

Projects must demonstrate feasibility within the proposed timeline and budget.

Who Is Eligible?

Eligible applicants must meet all of the following criteria:

  • Principal Investigator is qualified and experienced in oncology or hematology research

  • Affiliated with an eligible organization that can legally receive grant funding

  • Study is conducted entirely within the United States

  • Institution can meet all regulatory, ethical, and compliance requirements

Both academic and research-based clinical institutions may apply, provided they can support interventional clinical research.

Why This Funding Matters

Relapsed or refractory DLBCL remains a challenging clinical area with complex treatment sequencing decisions.

This funding opportunity matters because it:

  • Supports evidence generation in under-studied treatment settings

  • Improves understanding of brentuximab vedotin’s role around CAR-T therapy

  • Encourages investigator-driven innovation in lymphoma research

  • Contributes to optimized care pathways for patients with limited treatment options

How to Apply

Step-by-Step Application Process

  1. Develop an interventional study concept aligned with the program focus

  2. Ensure the study addresses priority gaps in relapsed or refractory DLBCL care

  3. Prepare a detailed research proposal, including study design, objectives, and budget

  4. Submit the application through Pfizer’s designated online portal by the stated deadline

  5. Undergo structured scientific and internal review by Pfizer

  6. Receive notification of funding decision based on review outcomes

  7. Complete regulatory approvals and execute a formal grant agreement before project initiation

Regulatory and Compliance Requirements

Before funding is released, selected projects must provide:

  • Approved study protocol

  • Institutional Review Board (IRB) or ethics committee approval

  • All required regulatory and compliance documentation

Failure to meet these requirements may delay or prevent fund disbursement.

Common Mistakes to Avoid

  • Submitting non-interventional or observational study proposals

  • Proposing studies outside relapsed or refractory DLBCL

  • Failing to address pre-CAR-T or peri-CAR-T relevance

  • Underestimating regulatory or ethical approval timelines

  • Submitting budgets that lack justification or feasibility

Frequently Asked Questions (FAQs)

What disease area does this funding opportunity cover?

The program focuses exclusively on relapsed or refractory diffuse large B-cell lymphoma.

What type of studies are supported?

Only interventional investigator-sponsored studies are eligible for funding.

Can studies be conducted outside the United States?

No. All funded studies must be conducted within the United States.

What is the maximum funding available per project?

Up to USD 500,000 per project, including allowable direct and indirect costs.

How long can a project run?

Projects may run for a maximum duration of four years.

Does Pfizer control the study design or outcomes?

No. All studies remain scientifically independent and investigator-led.

Are regulatory approvals required before funding?

Yes. IRB approval and all relevant regulatory documentation are required prior to fund disbursement.

Conclusion

Pfizer’s funding opportunity for investigator-sponsored studies on brentuximab vedotin in relapsed or refractory DLBCL offers a significant platform for advancing independent, clinically meaningful research.

By supporting interventional studies in pre-CAR-T and peri-CAR-T settings, the program aims to strengthen evidence-based decision-making and improve outcomes for patients facing complex lymphoma treatment pathways.

For more information, visit Pfizer.